Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer

DISEASE CHARACTERISTICS:

* Phase I:

  * Histologically or cytologically confirmed solid tumor

    * Metastatic OR locally advanced unresectable disease
    * No curative therapy exists
  * Measurable or evaluable disease

    * Measurable disease is defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension as ≥ 20 mm with conventional techniques OR ≥ 10 mm with spiral CT scan
  * No known brain metastases
* Phase II:

  * Histologically or cytologically confirmed colorectal cancer

    * Metastatic OR locally advanced unresectable disease
  * Measurable disease (as defined in phase I)
  * No tumor involving major blood vessels
  * No evidence of CNS disease, including primary brain tumor or brain metastases

PATIENT CHARACTERISTICS:

* Karnofsky performance status 70-100%
* Life expectancy ≥ 12 weeks
* Absolute neutrophil count (ANC) ≥ 1,500/mm\^3

  * ANC \< 1,500/mm\^3 allowed, if in the opinion of the investigator, this represents an ethnic or racial variation of normal
* Platelet count ≥ 100,000/mm\^3
* Hemoglobin \> 10.0 g/dL
* Bilirubin ≤ 1.5 mg/dL
* AST/ALT ≤ 2 times upper limit of normal (ULN)
* Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min
* Urine protein:creatinine ratio \< 1.0 OR protein \< 1 g by 24-hour urine collection (phase II)
* PT/INR ≤ 1.5 unless on full-dose anticoagulants (phase II)
* Not pregnant or nursing
* Negative pregnancy test
* Fertile female patients must use effective double-barrier contraception during and for 28 days (phase I) or 3 months (phase II) after completion of study treatment
* Fertile male patients must use effective contraception during and for 6 months after completion of study treatment
* No history of allergic reaction attributed to compounds of similar chemical or biologic composition to capecitabine, irinotecan hydrochloride, oxaliplatin, or bevacizumab
* No other uncontrolled illness including, but not limited to, any of the following:

  * Ongoing or active infection
  * Symptomatic congestive heart failure
  * Unstable angina pectoris
  * Cardiac arrhythmia
  * Psychiatric illness or social situation that would preclude study compliance
* No cardiac ischemia within the past 6 months (phase I)
* No New York Heart Association class II-IV congestive heart failure or symptomatic arrhythmia (phase II)
* No arterial thrombotic events within the past 6 months including, but not limited to, any of the following (phase II):

  * Transient ischemic attack
  * Cerebrovascular accident
  * Unstable angina or angina requiring surgical or medical intervention
  * Myocardial infarction
* No clinically significant peripheral vascular disease (phase II)
* No history of hypertension unless well controlled (\< 150/90 mm Hg) on an antihypertensive regimen (phase II)
* No evidence of bleeding diathesis or coagulopathy (phase II)
* No gastrointestinal (GI) perforation, abdominal fistula, or intra-abdominal abscess within the past 30 days (phase II)
* No significant history of bleeding events (phase II)

  * Patients with a history of significant bleeding episodes (e.g., hemoptysis or upper or lower GI bleeding) within the past 6 months are not eligible unless the source of bleeding has been resected
* No significant traumatic injury within the past 28 days (phase II)
* No serious or nonhealing wound, ulcer, or bone fracture (phase II)
* No peripheral neuropathy \> grade 1

PRIOR CONCURRENT THERAPY:

* At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered (phase I)
* At least 2 weeks since prior immunotherapy or biologic therapy and recovered (phase I)
* No prior treatment for advanced or metastatic colorectal cancer (phase II)
* More than 12 months since prior adjuvant chemotherapy and/or biologic therapy (e.g., bevacizumab or cetuximab) and recovered (phase II)
* At least 4 weeks since prior radiotherapy and recovered
* No prior radiotherapy to the only site of measurable disease unless there is measurable disease progression within the radiation port after completion of radiotherapy
* No prior radiotherapy to ≥ 20% of the bone marrow
* More than 28 days since prior major surgical procedure\* or open biopsy and recovered (phase II)
* More than 14 days since prior minor surgery\* and recovered (phase II)
* Concurrent full-dose anticoagulation (e.g., warfarin) allowed provided the following criteria are met (phase II):

  * Patient has an in-range INR (between 2 and 3) and is on a stable dose of oral anticoagulants or a stable dose of low molecular weight heparin
  * No active bleeding or pathological condition that carries a high risk of bleeding (e.g., known varices)
* No concurrent combination antiretroviral therapy for HIV-positive patients
* No other concurrent investigational agents
* No concurrent sargramostim (GM-CSF) NOTE: \*Insertion of a vascular device is not considered major or minor surgery